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Abstract
PCOS is often accompanied by insulin resistance, which is associated with the
pathogenesis of the syndrome and increases the risk of developing the metabolic
syndrome, type 2 diabetes, and cardiovascular complications. All these processes
are characterized by chronic inflammation, which may be associated with an
increased formation of reactive oxygen species and activation of inflammatory
pathways that may further aggravate the function of pancreatic beta-cells. It has
been shown that PCOS treatment improves metabolic indexes, while at the same
time lowering inflammatory indicators. This chapter summarizes the latest findings
about the role of oxidative stress and chronic inflammation in pathogenesis of
PCOS. It also provides information on genetic variability in these pathways that
may lead to interindividual differences in the risk for PCOS-related metabolic
complications. Furthermore, genetic variability in these pathways may influence
response to different treatment options in PCOS patients.
Keywords: PCOS, insulin resistance, chronic inflammation, oxidative stress,
reactive oxygen species, inflammatory pathways, metabolic syndrome
1. Introduction
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in
women in the reproductive period as it affects between 4 and 12% of the female
population. Nowadays, it is known that both genetic and environmental factors play
a role in PCOS development and its numerous clinical manifestations. The syn-
drome is characterized by hyperandrogenism, ovarian dysfunction and polycystic
ovaries, insulin resistance (IR), and chronic inflammation, all of which in the long
term also affects the post-reproductive period. It is associated with the increased
risk for infertility, depression, cardiovascular diseases (CVD), and endometrial and
even breast cancer [1].
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PCOS develops, when ovaries produce an excessive amount of male sex hor-
mones, androgens, in particular, testosterone and androstenedione. This occurs due
to two main reasons. The first one is irregular pulsative secretion of luteinizing
hormone (LH) from the adenohypophysis, which then increases the production of
androgens. The second mechanism is more complex, and it involves IR with associ-
ated increased concentration of serum insulin. Insulin stimulates pathways that
activate ovarian androgen production while at the same time lowering serum sex
hormone-binding globulin (SHBG) concentrations. Patients also intrinsically have
higher serum levels of gonadotropin-releasing hormone, which increases the ratio
between the LH and follicle-stimulating hormone (FSH). Higher ratio leads to
increased androgen production, slower follicle maturation, and decreased binding
of sex hormones on SHBG [2].
The choice of treatment is influenced by the desired goals, which in most cases
are the treatment for infertility and obesity and the reduction of symptoms of
hyperandrogenism. Clomiphene and letrozole are first-line medications for infertil-
ity. If patients do not desire pregnancy, hormonal contraceptives are recommended
for irregular menses and dermatologic manifestations. Metformin is the first-line
treatment for metabolic manifestations. Glucagon-like peptide 1 (GLP-1)-based
therapies and glitazones can be used in most severe cardio-metabolic PCOS
phenotypes that are resistant to first-line treatments [3, 4].
For quite some time, the subject of research has also been the involvement of
chronic inflammation and oxidative stress (OS) in the pathogenesis of PCOS.
Several studies have already confirmed that patients have elevated levels of OS and
inflammatory mediators and, on the other hand, have decreased antioxidant
capacity. There is also an unanswered question of the extent to which OS and
inflammation are causally related.
Research has already confirmed that genetic changes in key antioxidant
enzymes and inflammatory mediators can affect the individual’s defense ability
against OS and their predisposition to inflammation. Nowadays, molecular genetic
analysis is increasingly being used in clinical practice as it is a widely available
method, easily accessible and inexpensive. It also enables identification of groups
of patients with an increased risk of developing various diseases and offers a
patient-adapted treatment, thereby representing one of the pillars of personalized
medicine.
2. Chronic inflammation in PCOS
Inflammation is arguably involved to some degree in the underlying causes of
many chronic diseases. It is well known that different types of inflammatory cyto-
kines and chemokines are involved in female reproductive processes, including
ovulation, follicular development, fertilization, implantation, and pregnancy [5].
While the exact etiology of PCOS still remains unknown, the amount of evidence in
support of an important role of chronic low-grade inflammation in this process is
increasing. Chronic proinflammatory state in women with this syndrome is also
likely to be associated with other clinical manifestations and complications of
PCOS, including IR and CVD.
When studying the relationship between PCOS and chronic inflammation, it is
impossible to completely disregard the influence of increased body mass index
(BMI) in patients with increased inflammation markers. Similar to PCOS, low-
grade chronic inflammation is also present in metabolic syndrome (MS) [6]. This
proinflammatory state may be an important part of the pathogenesis of both
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syndromes and one of the reasons why they often overlap. The relationship between
them is mutual: PCOS women have a higher prevalence of MS, and alternatively,
women with MS commonly present the reproductive and endocrine traits of PCOS.
The visceral adipose tissue plays a key role in this overlap. It is more abundant and
metabolically active in both syndromes, which results in an increased turnover of
free fatty acids and an excessive secretion of several molecules, some of which are
inflammatory markers [7]. There is still not enough evidence to conclude whether
the proinflammatory state is intrinsic to PCOS, or it is rather only a consequence of
higher amounts of dysfunctional adipose tissue in those patients. In favor of the
latter theory are many studies which show that the higher the BMI in PCOS women,
the greater the inflammatory state. However, the fact that PCOS women with
lower BMI have more inflammation than healthy controls with higher BMI
indicates that chronic low-grade inflammation may not be dependent on
increased body mass only [8].
We can find the same degree of uncertainty in the relationship between chronic
inflammation and excessive androgen secretion in PCOS. It is unclear whether
androgen excess in PCOS promotes proinflammatory state or conversely whether
the inflammatory molecules stimulate ovarian androgen production and
hyperandrogenemia. Androgens influence the expression of different proteins and
enzymes in adipocytes and cause their hypertrophy. Also, hyperandrogenism in
PCOS increases mononuclear cell sensitivity to ingested glucose and promotes
activation of mononuclear cells. This leads to another important concept in PCOS:
diet-induced inflammation. Studies have shown that glucose ingested in vivo, as
well as glucose exposure in vitro, stimulates an inflammatory response by promot-
ing the mononuclear cells to release tumor necrosis factor alpha (TNFα) and inter-
leukin 6 (IL-6) [9]. Furthermore, infiltration of ovarian tissue by macrophages and
increased concentrations of TNFα and IL-6 in the follicular fluid (FF) have been
previously demonstrated in women with PCOS. It is possible to suspect that
mononuclear cells recruited into the polycystic ovaries cause a local inflammatory
response that stimulates CYP17, the ovarian steroidogenic enzyme, responsible for
androgen production. This establishes the vicious cycle, which indicates that
inflammation alone can promote androgen secretion, and this androgen excess can
stimulate inflammation through adipocyte hypertrophy and increased mononuclear
cell sensitivity to ingested glucose [9].
One of the most often used inflammatory markers is C-reactive protein (CRP).
It is primarily synthesized by the liver as an acute-phase protein. There is now
growing evidence that CRP has important roles in inflammatory pathways and host
responses to infection including the complement pathway, apoptosis, phagocytosis,
nitric oxide (NO) release, and the production of cytokines, particularly IL-6 and
TNFα [10]. The first study which demonstrated elevation of serum CRP concentra-
tions in women with PCOS was carried out by Kelly and associates in 2001. They
compared 17 women with PCOS and 15 healthy women and concluded that women
with PCOS had significantly increased CRP concentrations relative to women with
normal menstrual rhythm and normal androgen levels. They were also one of the
first to propose low-grade chronic inflammation as a novel mechanism contributing
to increased risk of CVD and type 2 diabetes in these women [11]. These findings
paved the way for numerous further studies. The first big meta-analysis of all these
studies was conducted in 2011 and included 3.648 women in total, and among them,
2.359 had PCOS and 1.289 were healthy controls. Mean serum CRP levels were 95%
higher in women with PCOS than controls. Elevated circulating CRP levels in
PCOS women were independent of obesity because the finding persisted after
excluding all the studies with mismatches in the frequency of obesity or body mass
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between groups from the meta-analysis [8]. Some studies examined the effects of
different treatment options on CRP levels. Metformin was shown to significantly
lower the CRP levels in different treatment protocols [12, 13]. Recent studies also
noticed that other PCOS management options, like statins or even increased
physical activity only, significantly decreased CRP levels in women with
PCOS [14, 15].
When considering other traditional inflammatory markers, females with PCOS
were reported to have significantly higher levels of serum monocytes, lymphocytes,
eosinophilic granulocytes, TNFα, and IL-6 than controls. Besides, in PCOS, ovarian
tissue has more macrophages and lymphocytes than controls. Lymphocytes and
macrophages secrete inflammatory cytokines like TNFα and IL-6, which in turn
activate more lymphocytes and macrophages to enhance further cytokine secretion
[9]. Especially TNFα seems to play a significant role in various clinical manifesta-
tions of PCOS. It is one of the most well-known inflammatory factors and has strong
scientific evidence to be an important mediator in processes such as obesity, IR,
and androgen expression. As a multifunctional hormone-like polypeptide, it has a
wide variety of physiological roles including many directly connected with ovaries,
such as regulation of ovarian function and exerting an influence on proliferation,
differentiation, follicular maturation, steroidogenesis, and apoptosis [16]. A meta-
analysis, published in 2016, which examined results from 29 studies with a total
of 1960 women (1046 PCOS patients and 914 controls), concluded that TNFα levels
in women with PCOS were significantly higher than healthy controls and that
high-serum TNFα concentration was related to IR and androgen excess but not to
the BMI [17]. TNFα is overexpressed in adipose tissue, so the source of excess
circulating TNFα in PCOS is mostly adipose tissue in the obese but remains
unknown in lean women with this disorder [18]. To even further emphasize the
important role of TNFα in PCOS, its concentration is not elevated on a systemic
level only but also in FF. Changes in FF levels of TNFα are associated with poor-
quality oocytes in women undergoing in vitro fertilization, which then leads to a
reduction in rates of fertilization, embryonic development, and pregnancy outcome
[16]. Among other mechanisms, TNFα production is also induced by another
proinflammatory cytokine interleukin 18 (IL-18), which was also reported to be
increased in PCOS. It is produced by macrophages and induces cell-mediated
immunity. Studies suggest that its levels are higher even in lean PCOS patients
and are correlated with IR and CVD risk [19, 20].
TNFα promotes the synthesis of two other important cytokines, IL-6 and
interleukin 8 (IL-8). IL-8 is mainly synthesized in macrophages and monocytes and
is a significant immune response modulator. However, there are more studies
regarding the role of IL-6 in PCOS, which has been closely associated with IR and
CVD. Obesity was reported to be correlated with elevated IL-6 levels. In contrast,
IL-6 levels decreased in PCOS patients after reducing their level of IR and body
mass. Although some studies reported significant elevations in IL-6 levels in
women with PCOS compared with controls, these findings were not confirmed in
similar studies, with some studies even reporting decreased IL-6 levels in patients.
However, a meta-analysis published in 2016, which included 922 PCOS patients
and 696 controls, suggested that IL-6 levels were higher in women with PCOS
than BMI-matched controls and that a high-serum IL-6 concentration was related
to IR and androgen levels, but not to the BMI [21]. In a research article published
in Mediators of Inflammation in 2011, authors concluded that IL-6 production
and serum levels are related to an altered immune response in PCOS women with
IR. They divided 44 young girls with PCOS aged 15–23 into non-IR and IR groups
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based on homeostatic model assessment (HOMA) findings. They were weight-
and age-matched with healthy young girls, and they measured a variety of different
inflammatory markers. The biggest difference between groups was in significant
higher IL-6 levels in IR PCOS patients. Moreover, in the PCOS group,
lipopolysaccharide-activated monocytes secreted significantly higher levels of
IL-6 [22].
Several studies investigated two other important cytokines, interleukin 10
(IL-10) and interleukin 1 (IL-1) family in PCOS patients. The former is an impor-
tant anti-inflammatory cytokine with multiple effects in immunoregulation and
inflammation. In a study including 61 PCOS patients and 80 healthy controls, IL-10
levels were significantly lower among PCOS patients [23]. On the other hand, IL-1
family is a group of 11 cytokines that are primarily associated with innate immunity
and are closely linked to a proinflammatory response. The IL-1 gene cluster on
chromosome 2 contains three related genes IL-1α, IL-1β, and IL-1RN, encoding the
proinflammatory cytokines IL-1α and IL-1β and their endogenous receptor antago-
nist. Previous PCOS research has been focused mainly on IL-1β since many studies
suggested its crucial role in inflammatory-linked mechanisms in the ovaries. It
probably intervenes in prostaglandin production, mainly by its activity on cycloox-
ygenase-2 synthesis. It also stimulates the production of other inflammatory
cytokines, such as IL-6 and interleukin 12 (IL-12) [24].
At the beginning of this century, Jurg Tschopp introduced the concept of the
inflammasome, and since then, inflammasomes have become an important topic of
immunological studies. The inflammasome is a macromolecular cytoplasm complex
that senses many different signals for cell damage on the molecular level and
initiates the inflammatory response. It promotes the maturation and secretion of
proinflammatory cytokines IL-1β, IL-18, and interferon gamma (IFNγ) and acti-
vates nuclear factor κB (NF-κB). There are many different types of inflammasomes,
but NLRP3 inflammasome is most commonly associated with obesity and IR. It
consists of three subunits: NLRP3, the adaptor protein apoptosis-associated speck-
like protein (ASC), and caspase-1. It initiates an inflammatory form of cell death
and triggers the release of proinflammatory cytokine IL-1β through the mechanism
of procaspase-1 cleavage. However, the role of NLRP3 inflammasome in the devel-
opment of PCOS remains largely unknown [25]. In a study published in 2017, the
NLRP3 and ASC mRNA levels, caspase-1 activation, and IL-1β production were
unregulated in PCOS patients, and those levels significantly improved after treat-
ment with dimethylbiguanide [26]. NLRP3 inflammasome may present an impor-
tant overlapping pathway between OS and chronic inflammation in PCOS, which
will be discussed in further detail in Chapter 4. In contrast with other previously
described inflammatory markers, there have been no published studies regarding
different genetic polymorphisms in NLRP3 inflammasome and PCOS at the time of
writing. However, there is a lot of evidence that gain-of-function polymorphisms
in the NLRP3 inflammasome play an important role in rheumatoid arthritis and
Crohn’s disease [27].
There has been a lot of progress in the pharmacogenetics of PCOS in recent
years. Its main goal is to find associations between genetic polymorphisms and the
course of the disease and response to treatment. In Table 1, we summarized main
studies which pointed out positive associations between different polymorphisms in
genes related to previously described inflammatory markers and PCOS risk or
clinical manifestations. At the time of writing, we could not find any study which
would explore the relationship between polymorphisms in those genes and
treatment response.
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Gene Variants Predicted effect Reference
TNFα rs1799964
1031 T > C
Susceptibility
The TT genotype was more frequent in controls
(p=0.0002) and TC genotype in patients (p=0.0003)
Clinical manifestations
TC genotype was associated with lower BMI (p = 0.03). TT
genotype was associated with early onset and
hyperandrogenism (p < 0.05)
[28]
Susceptibility
The frequency distribution of TT, TC, and CC genotypes
differed between PCOS and control group (p = 0.0003)
[29]
Susceptibility
A significant difference in allele transmission was found in
families with proband for PCOS (p = 0.0013)
[30]
rs1799724
857 C > T
Susceptibility
T allele showed a protective role against PCOS (p = 0.0032)
[31]
rs4645843
6213 C > T
Susceptibility
Genotype and allele distribution differed significantly
between PCOS patients and controls (p = 0.03 and 0.024,
respectively)
Clinical manifestations
Polymorphism was significantly associated with serum
testosterone levels (p = 0.01), HOMA-IR (p = 0.034), and
BMI (p < 0.05).
[32]
IL-6 rs1800795
174 G > C
Susceptibility
Genotype and allele distribution differed significantly
between PCOS patients and controls. The G allele
frequency was significantly higher in PCOS patients than
controls (all p values < 0.05)
[33]
Susceptibility
Polymorphism was associated with decreased PCOS
susceptibility in the overall population under the allelic
model (G vs. C, p = 0.005), the homozygous model (GG vs.
CC, p = 0.001), heterozygous model (GG vs. CG, p =
0.036), and the dominant model (GC+CC vs. GG, p =
0.020)
[34]
Susceptibility
G allele was more frequent in patients with
hyperandrogenism both when only homozygous and when
homozygous and heterozygous G allele carriers were
considered (p < 0.05 for all analyses)
[35]
Susceptibility
The genotype as well as the polymorphic G allele
distribution differed between PCOS patients and controls
(both p < 0.001)
[36]
Clinical manifestations
A relationship was detected between hirsutism, FSH, LH,
total testosterone, HDL-cholesterol and triglyceride levels,
and CG+GG genotypes. Furthermore, an association was
found between IL-6 levels and CC genotype in the obese
PCOS patients (p < 0.05 for all analyses)
[37]
rs1800797
597 A > G
Susceptibility
G allele was more frequent in patients with
hyperandrogenism both when only homozygous and when
homozygous and heterozygous G allele carriers were
considered (p < 0.05 for all analyses)
[35]
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Gene Variants Predicted effect Reference
IL-10 rs1800896
819 T > C
Susceptibility
The frequency of TT genotype was significantly increased
(p < 0.05) in PCOS group
[23]
Clinical manifestations
CT and TT genotypes were associated with lower total
cholesterol and triglyceride levels in PCOS patients (p < 0.05)
[38]
rs1800871
1082 A > G
Susceptibility
G allele was significantly increased among PCOS patients
(p < 0.01), while A allele was significantly increased (p <
0.001) in controls
[23]
Clinical manifestations
GA and AA genotypes were associated with lower total
cholesterol and triglyceride levels (p < 0.05)
[38]
rs1800872
592 C > A
Susceptibility
AA genotype carriers had increased risk of PCOS (p =
0.001)
[39]
Clinical manifestations
CA genotype was associated with lower total cholesterol
and triglyceride levels (p < 0.05)
[38]
IL-1β rs16944
511 T > C
Susceptibility
Both TT genotype frequency and T allele frequency were
significantly higher in PCOS patients than controls (both p
< 0.01)
[40]
Susceptibility
CC genotype frequency was significantly higher in PCOS
patients than controls (p < 0.001)
[24]
Clinical manifestations
T allele showed significant association with several metabolic
features associated with PCOS (p < 0.05 for all analyses)
[41]
Clinical manifestations
Both TT genotype frequency and T allele frequency were
significantly higher in obese PCOS patients than nonobese
patients (p < 0.05 for all analyses)
[42]
IL-18 rs187238
137 C > G
Clinical manifestations
C allele frequencies were significantly higher in PCOS
patients with IR than PCOS patients without IR (p = 0.048)
[43]
Susceptibility
CC and GC genotypes were associated with increased risk
of developing PCOS (p < 0.05)
[44]
Clinical manifestations
PCOS patients with GG genotype had a significantly
increased risk of impaired glucose regulation compared to
C allele carriers (p < 0.05)
[45]
IL-1α rs1800587
889 C > T
Susceptibility
The distribution of genotype frequencies was statistically
different in womenwith PCOS compared to controls (p = 0.04)
Clinical manifestations
The serum level of FSH and subsequent LH/FSH ratio
correlated with the polymorphism within the PCOS group (p =
0.005 and 0.01, respectively)
[46]
Table 1.
The associations between genetic polymorphisms in genes related to inflammatory markers and PCOS risk or
clinical manifestations.
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3. Oxidative stress in PCOS
OS has been a highly researched topic in the last two decades, due to the discovery
that imbalance between oxidants and antioxidants results in an abnormal redox state
of cells. This state is involved in the development of many diseases, such as diabetes,
cancer, atherosclerosis, depression, PCOS, and a few neurological diseases. OS
reflects an imbalance between production and scavenging of reactive oxygen (ROS)
and nitrogen species (RNS). The ROS include superoxide radical, hydrogen peroxide,
and hydroxyl radical, and the RNS include NO and its metabolites. Some ROS can
also act as cellular messengers. The peroxides and free radicals are unstable and
highly reactive and can damage different cell components. The most worrying long-
term effects are caused by the damage to the DNA [47, 48].
OS is considered as a potential inducing factor in the PCOS pathogenesis. In
most studies, PCOS patients present with higher levels of OS than controls.
However, results often vary, mainly due to the employment of different markers
and evaluation of the same marker in different sources and even with different
investigation methods. Moreover, OS is not necessarily associated only with PCOS
pathogenesis, since many clinical manifestations of PCOS, like hyperandrogenism,
obesity, and IR, may be a contributing factor in the development of the local
and systemic OS, which may then reciprocally worsen those metabolic
abnormalities [49].
Levels of molecular markers that could reflect the systemic OS, such as oxidized
low-density lipoprotein, malondialdehyde, thiobarbituric reactive substances, and
advanced oxidation protein products, were significantly increased in obese people
as compared with controls. On the other hand, markers that could reflect antioxi-
dant activity such as glutathione peroxidase (GPx) and superoxide dismutase
(SOD) were significantly decreased in obese as compared to controls. However,
obesity is probably only a contributing factor to OS in PCOS. When obese patients
are ruled out based on BMI, nonobese women with PCOS still have higher OS
markers than healthy controls [47].
One other important contributing factor to OS in PCOS women is IR. The
mechanism behind this is that hyperglycemia and higher levels of free fatty acids
lead to ROS production. On the other hand, OS can be an important factor in the
development of IR. There is a well-known phenomenon called OS-induced IR. The
full mechanism behind it is still unknown, but it was reported in multiple studies
that exposure to OS inhibits insulin-stimulated glucose uptake, glycogen, and pro-
tein synthesis. Increased OS activates various protein kinases, which induce serine
or threonine phosphorylation on insulin receptor substrate (IRS) instead of normal
tyrosine phosphorylation. This reduces the ability of the IRS to combine with the
insulin receptor and suppresses its activation of downstream phosphatidylinositol 3-
kinase. Furthermore, the wrong phosphorylation could also induce the degradation
of IRS. Insulin signaling pathways could also be activated by OS through Jun
N-terminal kinase/stress-activated protein kinase signaling pathway and inflamma-
tory signaling pathway (IκB kinase/NF-κB), leading to IR via post-insulin receptor
defect [47].
Antioxidants, on the other hand, are a class of molecules that can reduce the
destructive effects of free radicals. In general, we can divide antioxidants into two
groups: enzymatic like (SOD, catalase (CAT), GPx, glutathione reductase,
paraoxonase 1 (PON-1)) and nonenzymatic (glutathione, alfa-tocopherol, ascor-
bate, and beta-carotene). These antioxidants have already been reported to have an
important role in the female reproductive system and the pathogenesis of female
infertility [50].
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In general, chemical substances used for evaluation of OS status can be
divided into chemical components modified by ROS, ROS scavenging enzymes
or antioxidative chemicals, and transcription factors regulating ROS production.
Many studies tried to evaluate OS markers in PCOS women, but due to small
study groups, results often varied. A meta-analysis of these markers was
published in 2013. It encompassed 63 different studies and included 4933
PCOS patients and 3671 controls. It showed that the serum concentrations of
several promoters and by-products of OS were significantly increased in
patients with PCOS compared with control women. Homocysteine concentrations
were 23% higher in PCOS patients than control women according to this
meta-analysis. Homocysteine induces OS by promoting ROS production, and
its high serum level makes a person more prone to endothelial cell injury. A 47%
increase was noticed in malondialdehyde, an end-product of lipid peroxidation
and a useful and frequently used marker of OS. On the other hand, some
circulating antioxidant markers were decreased in PCOS. Glutathione, which plays
a key protective role against OS, was decreased by 50%. A similar decrease was
noticed in the activity of PON-1, which is an antioxidant enzyme that prevents the
oxidation of lipoproteins and hydrolyzes atherogenic products of oxidative lipid
modification such as phospholipid peroxides and cholesterol ester hydroperoxides.
Contrary to what was expected, a meta-analysis found an increase in the SOD
activity in PCOS patients. An increase in that potent protective enzyme, scavenging
superoxide anion radical, may be interpreted as a compensatory mechanism in
response to the increased production of other oxidant molecules. This meta-analysis
did not find significant differences among patients with PCOS and control
women in NO levels, GPx activity, and total antioxidant capacity, although many
individual studies reported significant differences [49]. A similar increase in
some antioxidative enzymes has already been described in few other studies.
A study published in 2018 noticed a significant increase in CAT and SOD activity,
and their interpretation of those results focused on an inner stress-counterbalanced
effect [51].
Since a large proportion of studies indicated an important imbalance in the
oxidative status of patients with PCOS, there have been a few attempts to treat
patients with antioxidants. A single-blind randomized control trial involving 200
patients with PCOS was published in 2018. Patients were randomized into inter-
vention and control groups, and baseline serum levels of OS markers, antioxidant
enzymes, vitamins, and minerals were determined. Antioxidant supplementation
and placebo were given to the intervention and control groups, respectively. All
patients had ovulation induction with clomiphene and were followed up for 6
months. There was statistically significant difference in the serum levels of OS
marker, antioxidant enzymes, vitamins, and minerals between the two groups.
Not only did the antioxidant supplementation significantly improve oxidative status
in those patients, but it also significantly affected pregnancy rate [52]. A recent
study has also shown promising results with the mitochondria-targeted antioxidant
for PCOS IR in animal model [53].
Researches have already confirmed that genetic changes in key antioxidant
enzymes and inflammatory mediators can affect the individual’s defense ability
against OS and their predisposition to inflammation. In Table 2, we summarized
the main studies which pointed out positive associations between different poly-
morphisms in genes related to previously described oxidative markers and antioxi-
dant enzymes and PCOS risk or clinical manifestations. At the time of the writing,
we could not find any study that explored the relationship between polymorphisms
in those genes and treatment response.
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Gene Variants Predicted effect Reference
PON-1 rs705379
108 C > T
Susceptibility
Genotype distribution differed significantly between PCOS
patients and controls (p < 0.05)
[54]
Susceptibility
Association with increased risk of PCOS was observed in
three genetic models: allelic comparison, homozygote
comparison, and recessive comparison (p < 0.05 for all
analyses)
[55]
Susceptibility
Results show a significant association between PCOS and
this polymorphism (for T vs. C: p = 0.012, for TT vs. CC: p
= 0.005, for TT vs. TC+CC: p = 0.01)
[56]
Susceptibility
The TT genotype was more frequent in PCOS patients than
in controls (p < 0.01)
Clinical manifestations
Free androgen index levels were higher in patients with TT
genotype (p < 0.05)
[57]
rs854560
163 T > A
Susceptibility
Genotype and allele frequency distributions differed
significantly between lean controls and lean PCOS women
(p < 0.05). This polymorphism reduced the risk of PCOS in
lean but not in obese Indian women (p < 0.05)
Clinical manifestations
This polymorphism influenced glucose metabolism, lipid
parameters, and hyperandrogenemia in the study group (p
< 0.05 for all analyses)
[58]
Susceptibility
The association between polymorphism and a decreased
risk of PCOS was found in dominant model (p < 0.05)
[55]
rs662
575 A > G
Susceptibility
GG genotype and G allele frequencies were higher in
patients with PCOS than in control women (p < 0.05)
Clinical manifestations
Compared with patients with AA genotype, patients with
GG or AG genotype had significantly higher waist
circumference and fasting insulin and triglyceride levels,
patients with GG genotype had significantly higher waist-
to-hip ratio, and patients with AG genotype had
significantly higher HOMA index (p < 0.05 for all
analyses)
[59]
Susceptibility
Women with AG or GG genotypes had a 2.5-fold increased
risk of PCOS compared to AA genotype (p = 0.03)
[60]
Susceptibility
Polymorphism was significantly associated with PCOS
(for G allele vs. A allele: p = 0.02, for GG+AG vs.
AA: p = 0.043)
[56]
Susceptibility
GG genotype and G allele frequencies were higher in PCOS
than in controls (p < 0.05 for all analyses)
Clinical manifestations
Testosterone, free androgen index, and
dehydroepiandrosterone sulfate levels were higher in
patients with GG than in patients with the wild or the
heterozygous genotype group (p < 0.05 for all analyses)
[57]
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4. Interplay between oxidative stress and chronic inflammation
OS and inflammation are closely related pathophysiological processes, one of
which can be easily induced by another. They usually occur simultaneously, and
because of that, it is hard to distinguish them completely in pathological conditions.
On the one hand, inflammatory processes can induce OS through different
pathways. Phagocytic cells like neutrophils and macrophages produce large
amounts of ROS and RNS to destroy invading agents. During pathological inflam-
matory conditions, there may be an exaggerated generation of these reactive spe-
cies. Some of those diffuse out of their phagocytic cells and can induce localized
OS. The similar process happens in nonphagocytic cells, which can also produce
reactive species in response to proinflammatory cytokines [63]. Recent studies
have also shown that activation of multiple Toll-like receptors produces unbalance
between proinflammatory and anti-inflammatory cytokines, and this leads to the
insurgence of OS [64]. Moreover, the proinflammatory cytokine IL-6 has been
found to produce ROS through increased expression of nicotinamide adenine dinu-
cleotide phosphate oxidase 4 (NOX4) in non-small cell lung cancer. Similarly, the
NOX4 overexpression can then enhance IL-6 production, and that forms a
positive reciprocal feedback loop between these two mediators of inflammation
and OS [63].
On the other hand, OS has been shown to induce inflammation. Growth factors
and chemokines produced by inflammatory cells induce the overexpression of
several transcription factors, such as NF-κB, signal transducer and activator of
transcription 3 (STAT3), activating protein-1 (AP-1), and hypoxia-inducible factor-
1 (HIF-1). They also activate redox-sensitive signal transduction pathways such as
c-Jun N-terminal kinase and p38 mitogen-activated protein kinase (MAPK)
[65, 66]. OS also plays an important role in the activation of the NLRP3
inflammasome, which promotes the maturation and secretion of proinflammatory
cytokines IL-1β, IL-18, and IFNγ and activates NF-κB. NLRP3 inflammasome can be
activated in multiple ways by OS. Besides activation by transcription factors,
NLRP3 can be activated by ROS released from the damaged mitochondria and
oxidized mitochondrial DNA during apoptosis. In conditions of OS, the ROS causes
the thioredoxin-interacting protein, an inhibitor of endogenous antioxidant
thioredoxin, to dissociate from thioredoxin and to bind with NLRP3 leading to
additional activation of NLRP3 inflammasome [63]. Another possible mechanism
for NLRP3 inflammasome activation is through ROS-induced DNA base
Gene Variants Predicted effect Reference
GSTM1 deletion Clinical manifestations
Adolescent girls with PCOS with GSTM1-null genotype (no
active alleles present) presented significantly lower
testosterone concentrations than those with the GSTM1-
active genotype (p < 0.05)
[61]
SOD2 rs4880
47 T > C
Susceptibility
The prevalence of the C allele was significantly greater in
PCOS patients than in controls (p < 0.05)
Clinical manifestations
Patients carrying the C allele had significantly higher serum
LH levels and ratio of LH to FSH than patients with the TT
genotype (p < 0.05 for all analyses)
[62]
Table 2.
Associations between genetic polymorphisms in antioxidant genes and PCOS risk or clinical manifestations.
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modifications. Moreover, the OS-induced oxidation of the extracellular redox
potential of plasma cysteine and its disulfide cysteine has been shown to trigger
monocyte adhesion to vascular endothelial cells, activate NF-κB, and increase the
expression of proinflammatory cytokine IL-1β [63]. OS also induces heat shock
proteins, which in turn stimulate the production of proinflammatory cytokines and
expression of the adhesion molecules like E-selectin, intercellular adhesion molecule
1, and vascular cell adhesion molecule 1 [66].
All these pathways seem to connect OS and inflammation into a self-
perpetuating cycle. In pathological conditions where OS is the primary abnormality,
inflammation will eventually develop and will further accentuate OS. Conversely,
when inflammation is the main abnormality, OS will develop and will increase the
damage from inflammation. Therefore identification of the primary abnormality
could be extremely important in many conditions because its treatment could
resolve additional problems from secondary OS or inflammation [63].
When it comes to PCOS, there is not yet enough evidence to confirm that either
OS or inflammation is the main abnormality. However, the majority of studies
agree that both phenomena at least play an important role in the clinical
manifestations of that syndrome. One clinical manifestation that has been studied
for its role in both OS and inflammation is obesity. Adipocytes have been
identified as a source of proinflammatory cytokines which can then stimulate the
production of ROS and RNS by macrophages and monocytes. One possible trigger
for adipose tissue production of those cytokines is hypoxia. Adipose tissue
hypoxia may underlie the dysregulated production of adipocytokines. In obese
patients, adipose tissue also has the secretory capacity of angiotensin II, which
stimulates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activ-
ity. NADPH oxidase comprises the major route for ROS production in adipocytes.
The second clinical manifestation that has already been connected with both OS
and inflammation is IR. OS has been recently recognized as one of the key mecha-
nisms in IR. The hypothesis that inflammation is causally linked to IR is supported
by clinical evidence of correlations between inflammatory markers and measures
of IR and also by biochemical evidence indicating that proinflammatory markers
can interfere with insulin action by directly inhibiting insulin receptors [67]. IR
then plays a key role in hyperandrogenemia, likely due to compensatory
hyperinsulinemia. Insulin is reported to stimulate ovarian androgen secretion
directly alone and/or through augment LH-stimulated androgen secretion.
Studies show that excessive activation of androgen receptor may provoke
systemic OS. In vitro, OS was also reported to enhance the activities of ovarian
steroidogenesis enzymes [47, 68]. Considering all previously discussed pathways,
it seems that all the described changes—inflammation, OS, obesity, IR, and
hyperandrogenism—interact among themselves and amplify each other in PCOS
patients [69].
5. Conclusions
The majority of studies confirm that PCOS patients have elevated levels of OS
and inflammatory mediators and that OS and inflammation may play an important
role in the pathogenesis of the syndrome and its clinical manifestations. There are
also several possible pathways how those two processes could form positive recip-
rocal feedback between each other and also between clinical manifestations of
PCOS, such as obesity, IR, and hyperandrogenism.
Given the importance of OS and inflammation in PCOS, many researchers have
tried to find associations between different polymorphisms in genes related to these
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pathways and PCOS risk, clinical manifestations, or treatment response. Evidence
shows that different genetic polymorphisms in those pathways have an important
role in susceptibility for the development of PCOS and that they greatly influence
its clinical manifestations. There is still a lack of studies that would evaluate how
those polymorphisms affect individual treatment response. Large pharmacogenetic
studies would improve our understanding of PCOS pathogenesis, and they could
identify polymorphisms potentially used as a predictive biomarker for evaluating
the risk for developing PCOS and for predicting treatment response in an individual
patient.
Abbreviations
AP-1 activating protein-1
ASC apoptosis-associated speck-like protein
BMI body mass index
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CRP C-reactive protein
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FF follicular fluid
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GPx glutathione peroxidase
HIF-1 hypoxia-inducible factor-1
HOMA homeostatic model assessment
IFNγ interferon gamma
IL-1 interleukin 1
IL-6 interleukin 6
IL-8 interleukin 8
IL-10 interleukin 10
IL-12 interleukin 12
IL-18 interleukin 18
IR insulin resistance
IRS insulin receptor substrate
LH luteinizing hormone
MAPK mitogen-activated protein kinase
MS metabolic syndrome
NF-κB nuclear factor κBNOnitric oxide
NOX4 nicotinamide adenine dinucleotide phosphate oxidase 4
OS oxidative stress
PCOS polycystic ovary syndrome
PON-1 paraoxonase 1
RNS reactive nitrogen species
ROS reactive oxygen species
SHBG sex hormone-binding globulin
SOD superoxide dismutase
STAT3 signal transducer and activator of transcription 3
TNFα tumor necrosis factor alpha
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